Position in ZYME
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$2,071,459
+$874,498 QoQ
Shares Held
82,726
+82.0% QoQ
Ownership
0.113%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026MACKENZIE FINANCIAL CORP holds $416,098,776 across 43 Biotechnology names. ZYME ranks #22 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TECH |
BIO-TECHNE Corp
|
1,779,636 | $93,003,777 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
86,317 | $66,691,966 | |
| 3 | INCY |
Incyte Corp
|
549,633 | $51,731,457 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
96,709 | $43,184,436 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
441,444 | $24,937,171 | |
| 6 | PTCT |
Ptc Therapeutics, Inc.
|
345,683 | $23,551,382 | |
| 7 | MRVI |
Maravai Lifesciences Holdings, Inc.
|
6,306,425 | $17,847,182 | |
| 8 | RPRX |
Royalty Pharma plc
|
170,882 | $8,197,209 |
All Filings in ZYME
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,071,459 | 82,726 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $1,196,961 | 45,460 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $962,919 | 56,377 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $268,005 | 21,355 | Shares | Sole | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||